You just read:

Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants

News provided by

Therabron Therapeutics, Inc.

25 May, 2016, 08:45 ET